FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Perrin Steven				2. Issuer Name and Ticker or Trading Symbol Eledon Pharmaceuticals, Inc. [ELDN]						(Che	Relationship of Reporting Pers (Check all applicable) X Director			uer wner		
(Last) (First) (Middle) C/O ELEDON PHARMACEUTICALS, INC. 19900 MACARTHUR BLVD STE, 550					3. Date of Earliest Transaction (Month/Day/Year) 02/01/2023						Officer (below)	give title President	Other (specify below)			
(Street) IRVINE (City)	C.	A	92612 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line) <mark>K</mark> Form fil	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2. Transaction 2. Transaction 2. Transaction 2. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature of																
Date			ite onth/Day/	Day/Year) Execution Date, if any (Month/Day/Year)		Code (Instr.		str. 3, 4 and 9	Securities Beneficia Owned Fo	lly (D) or	Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amount	ount (A) or (D)		Transacti (Instr. 3 a			(IIIStr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	Conversion Date Execu or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date, if any (Month/Day/Year	Code (Instr.		Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownershi Form: y Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
_				Code	v	(A)		Date Exercisable		cpiration ate	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (right to buy)	\$3.08	02/01/2023		A		155,000		(1)	02	2/01/2033	Common Stock	155,000	\$0.00	155,000) D	

1. This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2027.

Remarks:

/s/ Steve Perrin

02/02/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.